Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Bristol Myers Squibb

Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade

Bristol Myers Squibb shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Has Consumer Products Giant Bristol-Myers Squibb Kicked Into High Gear?

A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?

Investors Business Daily

New schizophrenia drug ‘could change the lives of millions of people’

The US Food and Drug Administration has approved Cobenfy, which is owned by pharmaceutical firm Bristol Myers Squibb.

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Cobenfy Gets FDA Approval: New Drug Offers Novel Treatment Mechanism For Schizophrenia

The new drug Cobenfy promises to revolutionize treatment for schizophrenia with its novel mechanism, the first of its kind in decades.

Medical Daily

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?

Pharmaceutical stocks largely shook off the brunt of negotiated drug prices. But that doesn't mean they'll be spared election noise.

Investors Business Daily

Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win

Bristol Myers Squibb stock gapped higher Friday after the Big Pharma stalwart beat June-quarter forecasts and raised its outlook.

Investors Business Daily

Catalyst's New CEO Has Big Ideas For The Small Biotech

Richard Daly has watched Catalyst Pharmaceuticals transform. Now, as the company's new CEO, he has some metamorphic ideas of his own.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

$100-million facility of Bristol Myers Squibb opened in Hyderabad

Bristol Myers Squibb opens new facility in Hyderabad, investing over $100 million to expand global capabilities.

The Hindu

Bristol Myers Squibb Reports Strong Q4 Results

Bristol Myers Squibb (BMY) reports strong Q4 results, faces biosimilar competition, but shows growth potential.

Top News

Senators ask CEOs why their drugs cost so much more in the U.S.

The Senate HELP committee questioned pharmaceutical CEOs about how much more Americans pay for the same drugs sold for less in Canada, Japan and Europe.

WEKU

Merck, Johnson & Johnson CEOs agree to appear before Senate HELP - Roll Call

Two drug company CEOs have agreed to testify before the Senate HELP Committee on drug prices, avoiding a scheduled subpoena vote on Jan. 31.

Roll Call

Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review

The major indexes will end 2023 with big annual gains and the Dow Jones at record highs.

Investors Business Daily

Nasdaq Posts a Record High on Strength in Chip Stocks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.42%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.43%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.60%. Stocks on Tuesday settled moderately higher, with the...

Barchart

Stocks Climb on Strength in Chip Stocks and Energy Companies

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.27%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.42%. Stocks this morning are moderately higher in thin holiday...

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Santa Claus Rally In High Gear For Dow; Tesla Eyes 2024 Growth Phase As China Deliveries Surge

The Dow was up more than 0.3% as was the S&P 500, while the Nasdaq climbed 0.4%. The small-cap Russell 2000 added to recent hefty gains.

Investors Business Daily

Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%

Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower.

Barchart

Markets Today: Stocks Modestly Higher in Thin Holiday Trade

Morning Markets March E-Mini S&P 500 futures (ES H24) are up +0.09%, and March Nasdaq 100 E-Mini futures (NQH2 4) are up +0.15%. Stock index futures this morning are modestly higher in thin holiday trade, with markets in Europe and parts of Asia closed for Boxing Day. Stocks are supported...

Top News

Bristol Myers Squibb Acquires Karuna Therapeutics in Billion Deal

Bristol Myers Squibb is set to acquire Karuna Therapeutics in a billion deal, expanding its neuroscience portfolio with the promising antipsychotic dru...

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio

Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal

Investors Business Daily

Bristol's $14 Billion Takeover Of Karuna Pulled A Bevy Of Stocks Higher

Bristol Myers Squibb announced its $14 billion acquisition of Karuna Therapeutics on Friday, sending KRTX stock into the stratosphere.

Fortune

Developing new medicines for everyone, everywhere, equally

The pharmaceutical industry’s role as healer is sorely diminished if we don’t develop medicines fairly for everyone who needs them.

Investors Business Daily

Bristol Myers Skids After Pushing Back A Key $10 Billion Sales Milestone

Bristol Myers Squibb pushed back sales expectations for its new drugs by a year early Thursday, and BMY stock tumbled.

Investors Business Daily

Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Price

Bristol Myers Squibb offered to buy Mirati Therapeutics for up to $5.8 billion, but MRTX stock tumbled on the lowball price.

The Guardian - US

Biden names 10 drugs for first negotiations to cut Medicare prices

Government claims prices could fall for 9m seniors but pharma companies claim cost-reduction program is unconstitutional

Investors Business Daily

The Unexpected Bad News For Novo's Ozempic In Biden's Drug Negotiations List

Drugs from AbbVie, Bristol and Merck took slots on the list of drugs subject to price cuts. But the pharmaceutical stocks were unmoved.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.